Sunshine Biopharma (SBFM) Assets Average (2011 - 2026)

Sunshine Biopharma has reported Assets Average for 14 years, with the latest figure at $29.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 2.91% year-over-year to $29.0 million; the trailing twelve-month figure through Mar 2026 stood at $29.0 million (down 2.91% YoY), and the FY2025 full-year result was $30.3 million, up 4.72% from the prior year.
• Assets Average for Q1 2026 stood at $29.0 million, down from $30.8 million in the prior quarter.
• The five-year high for Assets Average was $41.4 million in Q3 2022, with the low at $7.8 million in Q1 2022.
• Historically, Assets Average has averaged $29.1 million across 5 years, with a median of $29.7 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average surged 1818.4% — and 2023, when it sank 32.34%.
• Sunshine Biopharma's Assets Average stood at $35.1 million in 2022, then declined by 21.55% to $27.5 million in 2023, then grew by 10.22% to $30.3 million in 2024, then rose by 1.57% to $30.8 million in 2025, then fell by 5.78% to $29.0 million in 2026.
• The last three Assets Average figures came in at $29.0 million (Q1 2026), $30.8 million (Q4 2025), and $31.7 million (Q3 2025), per Business Quant data.